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The purpose of the present study was to develop a bilayer 
tablet of zolpidem tartrate (ZT) using sodium starch glycolate (SSG) 
as superdisintegrant in the immediate release (IR) layer and 
hydrophilic polymers such as hydroxypropyl methylcellulose (HPMC 
K4M), metalose 90 SH 4000, carbapol 974 PNF in sustained release 
(SR) layer. Both the IR and SR granules of ZT were evaluated for 
bulk density, tapped density, angle of repose, Carr’s index, Hausner 
ratio and loss on drying. All the values were found to be satisfactoy. 
The prepared bilayer tablets were evaluated for weight variation, 
hardness, friability, drug content, in vitro drug release, FT-IR 
studies, similarity factor and stability studies.  In vitro dissolution 
studies were carried out in a USP dissolution apparatus I using 
500mL of 0.01N HCl as dissolution medium. The formulations gave 
an initial burst effect to provide the loading dose of the drug 
followed by sustained release for 4 h. The data obtained were fitted 
to Zero order, First order, Higuchi’s model and Korsmeyer-Peppas 
equations. The release exponent (n) values for all the formulations 
were less than 0.45 indicating Fickian diffusion was the drug release 
mechanism. FT-IR studies indicated that there are no drug-excipient 
interactions. The similarity factor (f2) was calculated by comparing 
dissolution data of all the formulations with that of marketed bilayer 
tablet of ZT (Ambien CR). The f2 value was highest (70) for the 
formulation SF8 and was selected as promising formulation among 
all the developed formulations. The stability study was performed on 
the formulation SF8 at 25oC/60% RH, 30oC/75% RH and 40oC/75% 
RH (accelerated condition) for 3 months. The results indicated that 
there were no significant changes in aforesaid tablet properties.  
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INTRODUCTION 
About 25% of the adults experience 
insomnia at some time of their life and at least 
1 in 10 of the general population have its 
chronic form (Mendelson et al., 2004, Sateia et 
al., 2004). It is associated with impaired 
concentration and daytime functioning, 
reduced health-related quality of life and an 
increased risk of depression (Walsh et al., 2004). 
The treatment options currently available for 
insomnia are benzodiazepines receptor 
agonists, nonbenzodiazepine hypnotics and off-
label use of sedating antidepressants (National 
Institutes of Health, 2005). The problem 
associated with benzodiazepines receptor 
agonists are residual daytime sleepiness, 
anterograde amnesia and, importantly, 
withdrawal symptoms on discontinuation of 
therapy (Zhdanova et al., 2004). Off-label 
antidepressants such as trazodone or the 
tricyclic doxepin are also commonly used in 
insomnia treatment. However, this agent carries 
a risk of hypotension, dizziness, and daytime 
sedation, and doxepin in particular is associated 
with cardiotoxic effects (Ebert et al., 2006). The 
non-benzodiazepine hypnotics generally 
represent an improvement over benzodia-
zepines as a result of improved binding 
selectivity towards α1-containing receptors and 
enhanced pharmacokinetic properties such as 
bioavailability, plasma half-life, elimination rate, 
and blood-brain barrier penetration influence 
the onset and duration of hypnotic effects.  
Zolpidem tartrate belongs to the α-1 
GABAA receptors selective imidazopyradine 
group of compounds with intermediate potency 
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at α2 and α3 receptors and negligible activity at 
α5 receptors (Puia, 2001, Sanna et al., 2002).  
The oral bioavailability of ZT is 70% due to its 
first pass metabolism in liver. In addition, it has 
short biological half-life of 2.5 hr (Drover, 
2004, Krystal, 2009). Above properties make 
ZT a suitable candidate for the development 
into a SR formulation.  
The main objective in designing 
sustained or controlled delivery systems is to 
reduce the frequency of the dosing or to 
increase effectiveness of the drug by 
localization at the site of action and to reduce 
the dose required or providing uniform drug 
concentration in systemic circulation for 
prolonged period of time (Rahman et al., 2006).  
The multilayered tablet concept has been 
long utilized to develop SR formulation. Such a 
tablet is generally having a fast releasing layer 
and may contain bi- or triple layer to sustain the 
drug release (Abraham et al., 1997).  Bilayer 
tablet is suitable for sequential release of two 
drugs in combination (Ramesh et al., 2010, 
Reddy et al., 2010), separate two incompatible 
substances and also for SR tablet in which one 
layer is IR as initial dose and second layer is 
maintenance dose (Swamy et al., 2011, Kumar et 
al., 2010). In the latter case the bilayer tablet 
allows a portion of the drug to be released 
immediately, with a slower release of the 
remaining content for steady plasma 
concentrations. 
The purpose of the present study was to 
develop bilayer tablet of ZT with the goal to 
provide greater flexibility in treating both sleep 
onset and sleep maintenance difficulties in 
patients and letting individuals to awaken in the 
morning without feeling residual side effects 
whch is common with original zolpidem by 
maintaining constant plasma concentrations        
of ZT during the middle portion of the night 
(3-6h after dosing) (Moen et al., 2006). The 
polymer such as HPMC K5M, carbopol 974P 
and Metalose 90 SH 4000 were used in SR layer 
as release retardant. Superdisintegrant used was 
SSG in IR layer. 
 
MATERIAL AND METHODS 
Zolpidem tartrate, gifted by Aurobindu 
Pharma Ltd, Hyderabad, India, was used as 
active pharmaceutical ingredient. Lactose 
monohydrate (Pharmatose 200M) and sodium 
starch glycolate (SSG, Primojel) were obtained 
from DMV-Fonterra exipients GmbH & Co. 
KG, Klever Strasse Goch, Germany. 
Microcrystalline cellulose (MCC, Avicel PH101) 
was supplied by FMC BioPolymer, Bangalore, 
India. Hydroxypropyl methylcellulose (HPMC 
K4M, HPMC E5 LV premium), Carbapol 974P 
NF, opadry pink and opadry blue were 
purchased from Colorcon Asia Pvt Ltd, Goa, 
India. Metalose 90 SH 4000 was obtained from 
Shin Etsu Chemical Co., Ltd, Chiyoda-ku, 
Tokyo, Japan. Other chemicals are off 
analytical grade. 
 
Drug-excipient interaction study 
Drug-excipient interaction study was 
carried out by FT-IR technique (FTIR-1700, 
Shimadzu, Kyoto, Japan) in order to determine 
the interaction of ZT with the excipients used 
in the formulation. The pure drug, IR layer, and 
SR layer were scanned in KBr discs in the range 
of 4000–500cm–1. 
 
Solubility study of the drug in different 
media 
Solubility study was carried out in 
different medium over the pH range 1- 8.0 in 
order to acertain variable solubility of ZT. An 
excess quantity of ZT was taken in each of the 
medium (10mL) and was shaken in water bath 
shaker for 24h at 37ºC (Mutalik et al., 2007). 
The solution was then passed through a 
Whatmann (No-1) filter paper. The filtrate was 
suitably diluted and the amount of drug 
dissolved was determined spectrophoto-
metrically at 294nm. 
 
Preparation of bilayer tablet 
The SR bilayer tablets of ZT were 
prepared by wet granulation technique and the 
IR dose and maintenance dose or sustained 
dose was maintained at 6.436mg. The 
composition for IR and SR layer is shown in 
table I. 
 
Formulation of the immediate release 
layer 
The IR granules of ZT were prepared as 
follows. At first, the drug with lactose 
monohydrate, MCC, and SSG were passed 
through # 40 and mixed well in a double cone 
blender (Rinek, KALWEKA, HD-410AC) for 
10min at 25rpm. Binder solution  was  prepared 
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by dissolving HPMC E5 LV in water. The 
binder solution was then added to drug-diluents 
mixture and granulated in rapid mixer 
granulator (HSMG 1, Gansons Ltd., Thane, 
India). The granules were kept for drying in 
rapid dryer (TG 200, Retsch, UK) for 10min. 
After drying, the dried granules were passed 
through # 40 and loss on drying was checked. 
For lubrication, magnesium stearate was passed 
through # 60 and mixed with dried granules for 
5min.   
 
Formulation of sustained release layer 
Zolpidem tartrate along with other 
ingredients such as lactose monohydrate, MCC 
and HPMC K4M or Metalose 90 SH 4000 or 
Carbapol 974P were passed through # 40 and 
mixed well in double cone blender. The 
formulae for SR layer were given in table I. 
Other processing steps were similar to that of 
IR granules. 
 
Compression of bilayer tablet 
The accurate quantity of granules for IR 
were subjected to compression by using 16-
station single rotary machine (Cadmach-
CMD4) with B tooling having standard 
concave punch of 8.0mm diameter. These IR 
tablets were evaluated for various parameters 
such as hardness, friability, weight variation, 
content uniformity and in-vitro dissolution. 
The bilayer tablet of ZT was prepared by 
directly compressing the IR layer on to the SR 
granules. Then, it was compressed by using 
8mm flat face beveled edge punch with 
embosing y-on one side and 49 on other side. 
The prepared tablets were subjected to various 
evaluation tests. 
 
Characterization of pure drug, imme-
diate and extended release granules 
Pure drug and granules, prior to 
compression, were evaluated for bulk density, 
tapped density, angle of repose, Carr’s index, 
Hausner ratio, loss on drying and particle size 
distribution. Tapped density was carried out by 
using a digital tapped density apparatus 
(Electrolab-ETP-1020). Tapping was continued 
until the difference between successive volumes 
is less than 2%. Loss on drying was calculated 
by putting 1gm of granules on the pan of 
drying apparatus (Sartorius-MA 100, Germany) 
and the temperature was increased to 105oC 
(Martin et al., 2002).  
Table I. Other processing steps were similar to that of IR granules. Composition of immediate 



























Zolpidem tartarate 6.436 6.436 6.436 6.43 6.43 6.43 6.43 6.43 6.43 6.43 6.43 6.43
Lactose monohydrate 22.00 22.00 22.00 90.86 85.86 90.86 85.86 80.86 90.86 85.86 80.86 75.86
Microcrystalline 
cellulose 
99.01 98.36 96.41 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00
Sodium starch 
glycolate 
2.60 2.60 5.20 - - - - - - - - -
HPMC E5 LV 0.65 1.30 0.65 - - - - - - - - -
Hydroxy propyle 
methyl cellulose 
(HPMC) K4 M 
- - -
10.00 15.00 - - - - - - -
Metalose 90 SH -4000 - - - - - - - - 10.00 15.00 20.00 25.00




1.40 1.40 1.40 1.40 1.40 1.40 1.40 1.40 1.40
Water q.s q.s q.s q.s q.s q.s q.s q.s q.s q.s q.s q.s
Magnesium stearate 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3
Opadry blue 0.2 0.2 0.2 - - - - - - - - -
Opadry pink - - - 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
 
The weight of immediate release layer (F-IR class) was 130 mg and the total weight of bilayer tablet was 260mg. 
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Physical tests for the immediate release 
and bilayer tablets 
Immediate release and bilayer tablets 
were subjected to standard physical tests (Goto 
et al., 2004, Wu et al., 2009). Thickness was 
measured for five tablets by using Vernier 
calipers and the average was expressed in mm. 
Mass variation was determined by weighing 20 
tablets individually, the average mass was 
calculated and the percent variation of each 
tablet from the average value was determined. 
Hardness was determined by, randomly taking 
10 tablets from each batch, using Monsanto 
hardness tester (Electrolab Pvt. Ltd., India) and 
the average diametric compression pressure 
(Kg/cm2) to crush the tablets was determined. 
Friability was measured by weighing 20 tablets 
after dedusting and placing them in a Roche 
Friabilator (Electro lab, EF-2, mumbai, India), 
which was run at 25rpm for 4min. After 
dedusting, the tablets were weighed and the 
percent of friability was determined. For 
content uniformity, 20 tablets were randomly 
taken and powdered. The powder weight 
equivalent to 10mg of ZT was accurately 
weighed and transferred into a 100mL 
volumetric flask. Initially, 10 ml of 0.01N HCL 
was added and shaken for 10min. Then, the 
volume was made up to 100mL with same 
solution. The solution in the volumetric flask 
was filtered, diluted suitably and analyzed 
spectrophotometrically at 294nm (Revision 
Bulletin Official, 2011).  
 
In-vitro dissolution studies 
Dissolution test for prepared and 
marketed bilayer tablets of ZT was performed 
by USP dissolution testing apparatus 1 
(Electrolab TDT-08L, Mumbai), using 500mL 
of 0.01N HCl at 37±0.5°C as dissolution 
medium (Revision Bulletin Official, 2011). The 
rotational speed of basket was kept at 100 rpm. 
Ten milliliter of aliquotes were withdrawn at 5, 
10, 15, 30, 90, 120 and 240min and replaced 
with fresh dissolution media maintained at 
same temperature. The samples were passed 
through   membrane  filter  (pore  size, 0.45μm)  
and assayed immediately for ZT content by UV 
spectrophotometer at 294nm (UV-1800, 
Shimadzu, Japan). Dissolution test was also 
conducted for IR tablets  by  maintaining  same  
conditions and was carried out for 30min. This 
test was performed on 6 tablets and mean ± 
SD calculated. 
 
Drug release kinetics 
The kinetics of release of ZT from the 
prepared bilayer tablets were analysed by fitting 
in-vitro release data into Zero order, First order, 
Higuchi equation and Korsmeyer-Peppas 
equation (Patra et al., 2007) 
Zero order release equation : Qt= K0 t; First 
order release equation: Qt = Q0 e-K1t; Higuchi’s 
square root of time equation: Qt = KH t½; 
Korsmeyer-Peppas equation: Qt/Q∞ = Km tn;  
Where, Qt = amount of drug release at 
time t, Q∞ = amount of drug release after 
infinite time, Qt/Q∞ = fraction of drug release 
at time t, K0 = Zero order release rate constant, 
K1 = First order release rate constant, KH = 
Higuchi release rate constant, Km = constant 
depend on the structure and geometry of 
dosage form, n=release exponent which 
characterizes the mechanism of drug release, 
i.e. for cylindrical systems: n=0.45 for purely 
Fickian diffusion, between 0.45 and 0.89 for 
anomalous (non-Fickian transport) controlled 
by both diffusion and swelling, n=0.89 for 
zero-order release (swelling controlled drug 
release) systems, and values > 0.89 indicate 
super case-II transport (Siepmann et al., 2008) 
 
Statistical analysis 
The similarity factor (f2) given by scale-
up and post-approval changes (SUPAC) 
guidelines for modified release dosage forms 
was used as a basis for comparing dissolution 
profiles. This similarity factor is calculated by 
the following formula; 
f2 =50×log{[1+ (1/n) Σ (Rt–Tt)2]–0.5×100}   
Where n is the number of experimental 
points in the in vitro dissolution assay and Rt 
and Tt are the mean percentage of dissolved 
drug from the reference and test formulations. 
The similarity factor fits the result between 0 
and 100. Two dissolution profiles are 
considered similar when the f2 value is greater 
than or equal to 50 (Albertini et al., 2009). 
In the view of potential utility, the 
dissolution profile of optimized formulation 
(SF8) is compared with marketed bilayer tablet 
of ZT (AMBIEN CR). 
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Stability studies  
The optimized formulation (SF8) was 
subjected to stability study for 3 months at 
25°C/60% RH, 30°C/75% RH, and at 
accelerated condition (40°C/75% RH) in a 
stability chamber (JRIC 11, Osworld, Mumbai).  
At the   end   of   three   months,  tablets   were  
withdrawn and evaluated for various 
parameters like thickness, diameter, weight 
variation, hardness, content uniformity and 
dissolution.  
 
RESULT AND DISCUSSIONS 
Drug-excipient interaction study 
FT-IR spectra of pure ZT, IR layer and 
SR layer were presented in figure 1. The 
characteristic peaks of zolpidem tartrate         
were due to amide and alkene groups. There 
was no such significant change in the        
postion of major peaks in IR and SR layers 
indicating that no chemical reaction or 
interaction between the drug and excipients 
took place. 
 




















10.34±0.02 0.41±0.05 0.31±0.06 0.43±0.03 1.5±0.02 27.16±0.56 
Poor 
IF1  23.12±0.02 1.86±0.98 0.58±0.01 0.64±0.02 1.11±0.04 10.00±20.7 Excellent  
IF2  23.61±0.05 1.89±0.85 0.58±0.01 0.64±0.05 1.10±0.02 9.690±0.18 Excellent  
IF3  22.20±0.03 1.82±0.89 0.56±0.01 0.64±0.04 1.14±0.01 12.84±0.18 Good  
ER1  25.64±0.76 1.21±0.98 0.35±0.01 0.42±0.02 1.20±0.04 16.60±0.70 Fair  
ER2 25.56±0.67 1.10±0.85 0.36±0.01 0.43±0.05 1.19±0.02 16.20±0.18 Fair  
ER3 25.43±0.75 1.13±0.95 0.35±0.01 0.41±0.06 1.17±0.03 14.63±0.68 Good  
ER4 26.42±0.39 1.10±0.95 0.38±0.01 0.45±0.04 1.20±0.02 15.50±0.71 Fair  
ER5 26.03±0.59 1.11±0.85 0.35±0.01 0.42±0.05 1.18±0.02 15.43±0.65 Fair  
ER6 25.98±0.42 1.21±0.98 0.35±0.01 0.41±0.03 1.17±0.04 14.80±0.52 Good  
ER7 25.43±0.75 1.15±0.96 0.35±0.01 0.42±0.06 1.20±0.02 16.70±0.18 Fair  
ER8 26.03±0.59 1.11±0.86 0.35±0.01 0.42±0.05 1.18±0.02 15.43±0.65 Fair  
ER9 25.64±0.95 1.20±0.98 0.37±0.02 0.44±0.03 1.19±0.03 16.07±0.10 Fair  
 
































IF1 130±3 3.32±0.03 --- 1.1±0.3 0.43±0.35 36±0.01 99.88±0.61 
IF2   13±2 3.26±0.4 --- 0.9±0.5 0.68±0.08 40±0.02 99.28±0.31 
IF3 130±4 3.24±0.3 --- 1.2±0.2 0.72±0.15 35±0.06 98.12±0.08 
SF1  259±0.61 4.54±0.12 10.5±0.04  9.8±0.23 0.68±0.03 --- 101.63±0.21 
SF2 260±0.48 4.56±0.24 10.8±0.04  9.6±0.25 0.66±0.45 --- 98.34±0.07 
SF3 261±0.21 4.53±0.07 10.7±0.04  9.4±0.38 0.74±0.25 --- 99.28±0.31 
SF4 260±0.05 4.52±0.14 10.2±0.06  9.7±0.12 0.76±0.15 --- 98.12±0.08 
SF5 259±0.14 4.54±0.08 10.6±0.02  9.6±0.35 0.69±0.45 --- 97.29±0.47 
SF6 260±0.16 4.43±0.24 10.2±0.04 9.5±0.14 0.70±0.16 --- 98.14±0.02 
SF7 262±0.08 4.46±0.17 10.8±0.07 9.5±0.12 0.69±0.23 --- 97.29±0.25 
SF8 259±0.29 4.52±0.04 10.5±0.04 9.6±0.18 0.69±0.25 --- 99.43±0.18 
SF9 260±0.67 4.48±0.21 10.9±0.04 9.4±0.26 0.76±0.18 --- 98.03±0.13 
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Solubility studies of zolpidem tartrate 
The solubility of zolpidem tartrate in 
different medium such as 0.01 N HCL, 0.1 N 
HCL, pH 4.5 acetate buffer, pH 6.8 phosphate 
buffer, water and pH 7.2 phosphate buffer 
were measured and found that highest (48.72 
mg/ml) and lowest solubility (1.60mg/mL) of 
the drug was in pH 4.5 acetate  and  buffer  pH 
6.8 phosphate buffer, respectively. It was also 
confirmed that ZT showed pH dependent 
solubility. According to the biopharmaceutical 
classification system, a drug substance is 
considered as highly soluble when the highest 
does is soluble in 250mL or less of aqueous 
media over a pH range of 1-8. Highest dose of 
ZT is equivalent to 12.5mg and this is soluble 
in the entire pH range, hence it belongs to high 
soluble category.  
 
Physical Characteristics of pure drug, 
immediate and sustained release 
granules for all the formulation  
In the present investigation pure drug, 
IR and SR granules of ZT, prepared by wet 
granulation method, were evaluated for various 
physical characteristics and the values were 
presented in table II. The flow was poor for 
drug ZT, which necessitate the drug to be 
granulated. The bulk density for the granules of 
all the formulations ranged between 0.35±0.01 
and 0.58±0.01, which indicate good        
packing.  Resistance to particle movement         
can be judged from the angle of repose, which 
gives qualitative and quantitative assessment        
of   internal   cohesive    and    frictional   force.  
Values for angle of repose were found in the 
range of 26% to 30% and Carr’s index for all 
the formulation was found to be below 15%, 
indicating desirable flow properties (Staniforth, 
2002). This was further supported by             
Hausner ratio values which were in the range of 
1.04% to 1.17%. The loss on drying ranged 
between 1.1±0.85 to 1.89±0.85%. Hence the 
prepared blends possessed good flow 
properties and these can be used for tablet 
manufacture.  
 
Physical parameters of immediate 
release tablet 
All the IR tablets, prepared by wet 
granulation method, were subjected to various 
physical parameters and the data were shown in 
table III. All the formulations exhibited white 
colour, odourless, circular in shape with 
smooth surface. Weight variation of IR tablets 
was within 0.702%. Thickness and friability of 
all formulations were within acceptable limits. 
Hardness of all the three batches of tablets was 
in between 0.9±0.5 to 1.2±0.2kg/cm2. 
Disintegration time is very important for IR 
tablets and is desired to be less than 60sec. 
Disintegration time of prepared IR tablets was 
in the range of 35 to 40sec. 
 
Physical parameters of bilayer tablet 
All the batches of bilayer tablets were 
prepared under similar conditions to avoid 
processing variability and the data were 
presented in table III. Weight of bilayer tablet 
was 260±3 mg, thickness was 4.40±0.5 mm, 
diameter was 10.57±0.4 mm, hardness was 
9.56±0.22 kg/ cm2 and friability was 0.7±0.23 
%. Values of hardness test and percentage of 
friability indicate good handling properties of 
all the prepared bilayer tablets. The drug 
content uniformity in the bilayer tablets was 
98.62±0.19 %. 
 
In vitro dissolution studies 
In vitro dissolution studies of the 
prepared IR tablets was carried out in order to 
know better drug release profile among the IR 
formulations. The drug release at the end of 5 
minutes were found to be 49%, 45%, 62% and 
at the end of 30 minutes were found to be 
82%, 75% and 91% for IF1, IF2 and IF3, 
respectively. This result attributed to concentra-
tion level of SSG, as the concentration of SSG 
increased the drug release also increased. In 
addition, the drug release was less in case of 
formulation IF2 which was due to HPMC E5 
LV content. More the polymer amount less was 
the drug release. From the above formulation 
IF3 was selected as optimized IR layer.  
From the in vitro release study, it          
was observed that an initial burst release             
of  approximately  60%  of the active ingredient 
within 30 minutes in all the bilayer                   
tablet formulation (SF1-SF9) followed by a 
slower rate of release of the remainining ZT           
as shown in figure 2. The initial high amount  
of ZT release can be attributed to the                
drug release from IR layer and also due to 
presence   of   drug  on  the  surface  of  tablets.  
Rabinarayan Parhi 
Volume 24 Issue 4 (2013) 295 
The highest and lowest amount of drug          
release was shown by the formulation          
SF1 (99.91±0.17%) and SF7 (88.17±1.58%), 
respectively. 
Hydroxypropyl methylcellulose has been 
extensively used as rate controlling polymer in 
extended release dosage forms (Patra et al., 
2007, Ye et al., 2007, Al-Saidan et al., 2004). The 
rapid formation of a viscous gel layer upon 
hydration and the viscosity of HPMC regulate 
its performance in extended release matrix 
system (Rekhi et al., 1999). In the formulation 
SF1 and SF2, the controlled realse polymer was 
HPMC K4M used at 10 and 20mg/tablet. 
Initially rapid in vitro release (burst release) of 
approximately 91% and 82% of the active 
ingredient  within  30min  followed by a slower 
rate of release of the remaining 9% and 18% of 
ZT in the formulation SF1 and SF2, 
respectively. This could be due to the increased 
path length for the drug to diffuse from the 
matrix. Same trend of decrease in initial burst 
effect and cumulative percentage of drug 
release   was   observed   in    the   formulations          
(SF3-SF5) containing Carbopol 974P and             
the formulations (SF6-SF9) containing 
Metolose 90 SH 4000 as release retardant.           
In   case  of  formulation  containing  carbopol,  
 
 
Figure 1.  FT-IR spectra of (a) pure drug, (b) immediate release layer, and (c) sustained 




Figure 2.  Dissolution profile of all formulations (mean ± SD, n = 6) 
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the result was attributed to more rapid 
hydration of carbopol 974 P in 0.01 N HCl at 
lower concentration than at higher 
concentration. In addition carbopol 974P 
which has pKa of 6.0, remains unionized in the 
acidic environment of dissolution medium (Seta 
et al., 1988). It  was  found  that  bilayer  tablet  
with controlled release polymer Metalose 90SH 
4000  most  effectively  retarded  the  release  
of  drug  than  that  of other polymers (HPMC 
K4M, Carbopol 974 P NF) used. 
 
Drug release kinetics 
In vitro drug release data of all the bilayer 
tablet of ZT was fitted to different kinetic 
models like Zero order, First order, Higuchi 
and Korsmeyer-Peppas model to ascertain 
mechanism of drug release and the values 
obtained are presented in table IV. It was 
evident that the formulations SF6-SF9 
adequatly fit to Higuchi model (r2 values from 
0.959 to 0.989), indicating that diffusion is the 
release mechanism of drug from the tablets. 
For further conformation, release exponent (n) 
were calculated from Korsmeyer-Peppas 
equation and the obtained ‘n’ values were less 
than 0.45 for all the formulation, which 




Similarity factor was used for the 
comparison of release profile of different 
formulation. Here all the formulations were 
compared with that of marketed product 
(Ambien CR). The f2 value of all the 
formulations, from SF4 to SF9, was above 50 
which indicates that those formulations are 
having similar dissolution profile with the 
marketed product and it is highest (f2=70) for 
formulation SF8. In the view of above f2 
values, SF8 was selected as best formulation 
and was taken for stability study.  
 
Stability studies 
The physical parameters and in vitro 
dissolution profile for optimized formulation 
SF8 before and after 3 months of stability study 
were measured and found that there was no 
significant change in thickness, diameter, 
weight variation, hardness, content uniformity 
and in vitro dissolution profile of optimized 
formulation.   
 
Comparative dissolution profile of 
Innovator (Ambien CR) and optimized 
formulation (SF8) 
Among all the formulations, F8 
containing 2.60mg of SSG in IR layer and  
20mg of matalose 90 SH 4000 as controlled 
release polymer was showing similar to           
the innovator product in respect of all tablets 
properties. The percentage of drug release  
from   both   the  prepared  formulation F8 and 
AMBIEN CR was found to be between 49 to 
99%. The formulation F8 shows better 
percentage of drug release between 97 to 99%. 
From the above fact, it was concluded that ZT 
extended release bilayer tablets can be prepared 
successfully as it satisfies all the criteria as a 
Table IV. Drug release kinetics for different formulation of Zolpidem tartarate 
 







Korsmeyer  and 
Peppas 
Release exponentional in 
Korsmeyer & Peppas (n) 
SF1 0.554 0.504 0.756 0.899 0.126 
SF2 0.676 0.647 0.864 0.968 0.112 
SF3 0.6 0.534 0.788 0.904 0.136 
SF4 0.674 0.646 0.858 0.95 0.18 
SF5 0.682 0.646 0.867 0.963 0.175 
SF6 0.839 0.786 0.959 0.982 0.153 
SF7 0.909 0.87 0.988 0.977 0.108 
SF8 0.885 0.819 0.985 0.994 0.181 
SF9 0.897 0.833 0.989 0.993 0.167 
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bilayered tablet and would be alternative to the 
currently available conventional tablets. 
                                    
CONCLUSIONS 
The present research was carried out to 
develop a bilayer tablet of ZT (IR and SR layer 
each containing 6.43mg) using SSG for IR and 
HPMC K4M, Metalose 90 SH 4000, Carbapol 
974 PNF for the sustaining layer. Bilayer tablet 
showed biphasic release pattern where IR layer 
released more than 75% of ZT as burst effect 
followed by a controlled release from the 
matrix layer for up to 4 h, intended for 
overnight action. Among all the hydrophillic 
polymers, Metalose 90 SH 4000 showed better 
control over ZT and the formulation SF8 was 
found out to be promising formulation because 
of its highest similarity factor of 70 in 
comparison to marketed bilayer tablet of ZT 
(Ambien CR). Results of the current study 
clearly indicate, bilayer tablet of ZT was a stable 
dosage form and a promising potential of the 
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